Macquarie Group
GYRE icon

Macquarie Group’s Gyre Therapeutics GYRE Stock Holding History

Macquarie Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-408
Closed -$7 – 1996
2024
Q1 		$7 Buy
+408
New +$7.35K ﹤0.01% 1746
2019
Q3 		– Sell
-679
Closed -$38K – 1904
2019
Q2 		$38K Buy
+679
New +$42.4K ﹤0.01% 1748
2019
Q1 		– Sell
-107
Closed -$6K – 1816
2018
Q4 		$6K Buy
+107
New +$7.89K ﹤0.01% 2048
2018
Q1 		– Sell
-80
Closed -$8K – 2243
2017
Q4 		$8K Buy
+80
New +$4.08K ﹤0.01% 2306

Other funds holding GYRE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Macquarie Group's GYRE Position: Q2 2024 in Review

Macquarie Group sold out of Gyre Therapeutics (GYRE) in Q2 2024, closing a stake of 408 shares — an estimated $7 sold.

Macquarie Group first reported a position in GYRE in Q4 2017 and held it in 4 quarters. The position peaked at $38K in Q2 2019. 30 funds tracked by Wall St. Rank hold GYRE as of Q2 2024.

  • Macquarie Group reported no remaining Gyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 408 Gyre Therapeutics shares in Q2 2024, an estimated $7.
  • Macquarie Group first reported a position in Gyre Therapeutics in Q4 2017 and held it in 4 quarters.
  • Macquarie Group's Gyre Therapeutics position peaked at $38K in Q2 2019.
  • 30 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.